Talking to someone who is not from your field of work can be beneficial in mastermind sessions, as you often gain insights ...

周三，Maxim Group调整了对Brainstorm Cell Therapeutics (NASDAQ:BCLI)股票的展望，将目标价从之前的$30下调至$10，同时维持对该股的买入评级。这一决定反映了对公司ALS治疗药物NurOwn进展的谨慎但仍然乐观的看法。 Maxim Group的分析师引用了持续的数据，表明NurOwn可能对ALS的进展产生积极影响。分析师强调了3期b临床试验设计在确 ...

纽约 - 神经退行性疾病细胞疗法开发商BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI)周二宣布，该公司已重新符合纳斯达克资本市场持续上市的最低竞价要求。公司收到纳斯达克证券交易所的书面通知，确认其普通股已达到必要的竞价标准。 这一进展使BrainStorm的股票能够继续在纳斯达克资本市场上市，前提是公司满足纳斯达克设定的其他持续上市要求。对于拥有Nur ...

BrainStorm (BCLI) announced that the company received written notice from The Nasdaq Stock Market stating that the company has regained ...

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report). The company’s shares opened today at $1.95. According ...

The lowered price target reflects these complex factors as the company moves forward with its ALS treatment research. In other recent news, BrainStorm Cell Therapeutics Inc. successfully regained ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) ...

The company had received written notice from The Nasdaq Stock Market confirming that its common stock met the necessary bid price criteria. This development allows BrainStorm's stock to maintain ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

On Wednesday, Maxim (NASDAQ:MXIM) Group adjusted its outlook on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI), reducing the price target to $10 from the previous $30 while keeping a Buy rating ...

As more people turn to ChatGPT instead of Google, research shows AI can be a better tool for creative problem-solving – ...

As Donald Trump gets set to return to the White House, several big chip companies are racing to finalize deals under the 2022 ...